Published in J Cell Mol Med on December 01, 2008
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Epigenetics and cardiovascular disease. Nat Rev Cardiol (2010) 1.68
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis. J Oncol (2011) 0.94
Review: Epigenetic mechanisms in ocular disease. Mol Vis (2013) 0.91
MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. Circulation (2011) 0.84
Epigenetics: an expanding new piece of the stroke puzzle. Transl Stroke Res (2011) 0.79
Epigenetic modulation in the treatment of atherosclerotic disease. Front Genet (2014) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (1995) 15.15
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Phenotypic plasticity and the epigenetics of human disease. Nature (2007) 10.37
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 9.10
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell (2008) 7.26
miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell (2008) 6.59
Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet (1994) 6.50
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev (1994) 5.90
Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nat Rev Genet (2008) 5.67
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J (2002) 5.44
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet (1996) 5.15
Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res (2007) 5.09
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res (2007) 4.72
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A (1985) 4.60
Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem (2004) 4.40
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
MicroRNAs modulate the angiogenic properties of HUVECs. Blood (2006) 4.31
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One (2006) 4.29
Genome-wide approaches to studying chromatin modifications. Nat Rev Genet (2008) 4.28
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. Nat Rev Genet (2007) 3.98
Lymphangiogenesis and cancer metastasis. Nat Rev Cancer (2002) 3.90
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet (2006) 3.88
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev (2007) 3.34
Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J (2004) 3.17
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol (2005) 3.14
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med (2001) 3.07
Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell (2006) 3.07
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet (2004) 2.97
Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet (2006) 2.94
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A (2006) 2.90
Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature (2004) 2.90
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood (2007) 2.83
Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet (1999) 2.79
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res (2001) 2.70
Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62
Von Hippel-Lindau disease. Annu Rev Pathol (2007) 2.61
Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet (2003) 2.58
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes (2002) 2.46
Pericytes: cell biology and pathology. Cells Tissues Organs (2001) 2.36
Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development (2004) 2.35
Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 2.31
Vascular malformations. Part II: associated syndromes. J Am Acad Dermatol (2007) 2.31
ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood (2007) 2.17
Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem (2001) 2.15
Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest (2008) 2.15
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 2.12
Genetic heterogeneity of angiogenesis in mice. FASEB J (2000) 1.98
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis (2006) 1.97
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.94
Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci (2007) 1.88
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer (2003) 1.88
Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene (2005) 1.87
Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol (2002) 1.84
Endoglin in angiogenesis and vascular diseases. Angiogenesis (2008) 1.83
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res (2006) 1.81
Vascular malformations: Part I. J Am Acad Dermatol (2007) 1.74
miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum Mol Genet (2007) 1.73
Genetic causes of vascular malformations. Hum Mol Genet (2007) 1.69
Klippel-Trenaunay syndrome: diagnostic criteria and hypothesis on etiology. Ann Plast Surg (2008) 1.68
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol (2007) 1.68
MicroRNAs make big impression in disease after disease. Science (2008) 1.67
Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol (2005) 1.66
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res (2005) 1.66
Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol (2007) 1.59
Imaging and therapeutic approach of hemangiomas and vascular malformations in the pediatric age group. Pediatr Radiol (1999) 1.56
Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis (2003) 1.55
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet (1997) 1.54
Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet (2006) 1.52
Progranulin: normal function and role in neurodegeneration. J Neurochem (2007) 1.50
Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood (2002) 1.50
Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer (2002) 1.49
Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem (2005) 1.47
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax (2009) 4.86
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol (2011) 2.94
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation (2006) 2.88
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Robust cell polarity is a dynamic state established by coupling transport and GTPase signaling. J Cell Biol (2004) 2.56
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res (2009) 2.25
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol (2011) 2.10
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Single-molecule imaging of the H-ras membrane-anchor reveals domains in the cytoplasmic leaflet of the cell membrane. Biophys J (2004) 1.95
Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. Eur Heart J (2010) 1.90
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86
Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev (2007) 1.86